+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release New Study Demonstrates The Ability Of Prolaris To Predict Which Men With Prostate Cancer Will Benefit From Multi Modality Therapy is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release New Study Demonstrates The Ability Of Prolaris To Predict Which Men With Prostate Cancer Will Benefit From Multi Modality Therapy | RobinsPost News & Noticias

Prostate cancer isn’t always deadly — but here’s when it can be


radiation or targeted drug therapy. For many people, one of these treatments will work. An estimated 1 in 8 men will be diagnosed with prostate cancer, but only 1 in 39 (or 2.6%) men will die from ... Read More

Study Reveals Link Between Prostate Cancer And Heart Disease Among Black Men


Researchers are hopeful that the discovery will lead to treatments that will help improve the outcomes for Black men. A new study presents a link between prostate cancer and a disparity in ... Read More

Black Men Face Heightened Risk Of Prostate Cancer, Highlighted By O.J. Simpson’s Passing


Prostate cancer remains a significant health concern for Black men, who are disproportionately affected by the disease. Prostate cancer remains a significant health concern for Black men ... Read More

Lung Cancer News


Mar. 11, 2024 — Scientists trained a machine-learning algorithm to predict accurately brain metastasis using biopsy samples from early-stage non-small cell lung cancer patients. It was also ... Read More

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis


Results from the 12-week double-blind study period were previously published in The New England Journal of Medicine. University of Lille, CHU Lille, France From the initial 12-week double-blind ... Read More

O.J. Simpson died from prostate cancer: Why many men don't talk about this disease


Add on top of that the complications of prostate cancer in particular − which can include the loss of sexual function − and you have an illness that's especially difficult for men to admit ... Read More

The bold new way to publicly announce your break up: ‘Like a press release’


But one content creator has discovered an inventive and bold new way to share the heartbreaking ... almost like a press release,” she said. “I did it because it was silly, but also to give ... Read More

Prostate cancer is the second-leading cancer among men. Here's what to know about it


Cancer rates, especially among young people, are on the rise. There's expected to be 2 million new ... men in 2023 and 11% of cancer deaths. It's also the second-leading cancer among men. Prostate ... Read More

Ice therapy shown to kill breast cancer tumors in new study: ‘Important technique’


Ice could be the next frontier in breast cancer therapy, according to new research from Memorial ... not candidates for surgery, a press release stated. The study evaluated 60 patients who ... Read More

Prostate Cancer


For some people, taking part in a clinical study may be ... you access to promising new options. Other than skin cancer, prostate cancer is the most common type of cancer in U.S. men. Early detection ... Read More

Dog Company Announces New Air Travel Experience Designed Specifically for Canines: They 'Will Be the VIPs'


and their human companions second," according to a press release obtained by PEOPLE. Currently, routes will serve the New York City metro area through Westchester County Airport (HPN) with flights ... Read More

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis


New 48-week frexalimab ... as a potential high-efficacy therapy in relapsing MS.” From the initial 12-week double-blind period, 97% (125/129) of study participants entered the open-label ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus